Pay in 4 interest-free payments of $5.07 Learn more
Ships within 48 hours · Estimated delivery Sep 8 - Sep 13
They can: reduce appetite increase feelings of fullness slow gastric emptying help regulate blood sugar reduce food noise for some people For many women, this can make it easier to create a calorie deficit and lose weight
Key Takeaways Triple agonist mechanism: Retatrutide is the first medication to activate GIP, GLP-1, and glucagon receptors simultaneously GLP-1 component reduces appetite and slows gastric emptying, the core appetite suppression pathway GIP component improves insulin sensitivity and promotes favorable fat distribution Glucagon component increases energy expenditure through thermogenesis and promotes fat breakdown Weight loss: Phase 2 trials showed up to 24.2% weight loss at 48 weeks, compared to tirzepatide (~22%) and semaglutide (~15%) Investigational status: Not FDA-approved
Survodutide has received FDA Breakthrough Therapy designation for MASH (metabolic dysfunction-associated steatohepatitis), showing particular promise for liver-related conditions
Even small variations in storage conditions can have a noticeable impact on stability, which in turn may affect the reliability of experimental outcomes
